Dasiglucagon for treating congenital hyperinsulinism


featured image

Dasiglucagon is in clinical development for treating hypoglycaemia due to congenital hyperinsulinism (CHI) in children. CHI is an inherited disorder in which the body releases insulin even when it is not needed.

Interventions: Dasiglucagon (ZP 4207)
Year: 2021

Dasiglucagon is in clinical development for treating hypoglycaemia due to congenital hyperinsulinism (CHI) in children. CHI is an inherited disorder in which the body releases insulin even when it is not needed. Insulin is a hormone that helps control blood glucose (sugar) levels by driving glucose into the cells of the body. In hyperinsulinism, the increased amount of insulin causes hypoglycaemia (low blood glucose levels). The severity of CHI varies among patients and some patients develop episodes of hypoglycaemia shortly after birth. Repeated episodes of hypoglycaemia increase the risk of serious complications such as seizures (fits), mental disability, breathing difficulties and coma. CHI is a long-term debilitating condition because of the effects of long-term hypoglycaemia on the brain. There are limited effective treatments for CHI available and sometimes surgery is required if medical management does not keep a child’s blood glucose levels at an acceptable level.